Skip to main content

Bolt Biotherapeutics, Inc.

BOLT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001641281

In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Bolt Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
2 filings
2 insiders, $4.44K in total
Open-market sells
3 filings
3 insiders, $128.3K in total
Insiders trading
3
Net value
−$123.8K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Bolt Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Bolt Biotherapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Yonehiro GrantChief Operating Officer17,269Sep 21, 20264
Nemec SarahSenior VP, Finance and PAO17,082Sep 21, 20264
Quinn William P.President, CEO and CFO25,384Sep 21, 20264
Laporte KathleenDirector–Jun 11, 20262
Onetto NicoleDirector–Jun 11, 20262
O'Callaghan BrianDirector–Jun 11, 20262
Dupont JakobDirector–Jun 11, 20262
Berner LauraDirector–Jun 11, 20262
Healy JamesDirector–Jun 14, 20240
Shah MahendraDirector–Jun 14, 20240
Lee Frank D.Director–Jun 14, 20240
Schatzman Randall CChief Executive Officer–Mar 6, 20240
Perez Edith A.Chief Medical Officer37,042Mar 6, 20240
Engleman EdgarDirector251,522IndirectDec 1, 20230
Vivo Capital Fund VIII, L.P.10% Owner111,662IndirectNov 22, 20230
Vivo Capital VIII, LLC10% Owner111,662IndirectNov 22, 20230
Vivo Capital Surplus Fund VIII, L.P.10% Owner111,662IndirectNov 22, 20230
Vivo Panda Fund, L.P.10% Owner111,662IndirectNov 22, 20230
Vivo Opportunity, LLC10% Owner111,662IndirectNov 22, 20230
Vivo Panda, LLC10% Owner111,662IndirectNov 22, 20230
Vivo Opportunity Fund Holdings, L.P.10% Owner111,662IndirectNov 22, 20230
Miller Richard A MDDirector–Jun 14, 20230
Novo Holdings A/S10% Owner3,703,991Jul 15, 20220
Dornan DavidChief Scientific Officer–Feb 23, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 21, 2026 (view filing)6:05 PM ETSep 16-185 daysLateYonehiro GrantChief Operating OfficerSSale−13.2K$3.32−$43.8K−43.3%17.3K after3 lots
Sep 21, 2026 (view filing)6:04 PM ETJun 5108 daysLateNemec SarahSenior VP, Finance and PAOPPurchase+509$3.88+$1.97K+36.0%1.92K after
Sep 21, 2026 (view filing)6:04 PM ETSep 16-185 daysLateNemec SarahSenior VP, Finance and PAOSSale−7.84K$3.32−$26.1K−31.5%17.1K after3 lots
Sep 21, 2026 (view filing)6:03 PM ETJun 5108 daysLateQuinn William P.President, CEO and CFOPPurchase+637$3.88+$2.47K+27.5%2.95K after
Sep 21, 2026 (view filing)6:03 PM ETSep 16-185 daysLateQuinn William P.President, CEO and CFOSSale−17.6K$3.32−$58.4K−40.9%25.4K after3 lots
Feb 4, 2026 (view filing)Dec 5, 202561 daysLateQuinn William P.President, CEO and CFOPPurchase+125$4.61+$576.25+5.7%2.31K after
Feb 4, 2026 (view filing)Dec 5, 202561 daysLateNemec SarahSenior VP, Finance and PAOPPurchase+125$4.61+$576.25+9.7%1.42K after
Oct 24, 2025 (view filing)Jun 6140 daysLateNemec SarahSenior VP, Finance and PAOPPurchase+125$5.49+$686.25+15.3%943 after
Oct 24, 2025 (view filing)Jun 6140 daysLateQuinn William P.President, CEO and CFOPPurchase+125$5.49+$686.25+6.1%2.19K after
May 5, 2025 (view filing)Jun 6-Dec 16, 2024333 daysLateNemec SarahSenior VP, Finance and PAOPPurchase+5.00K$0.57+$2.85K+56.4%13.9K after2 lots
May 5, 2025 (view filing)Jun 6-Dec 16, 2024333 daysLateQuinn William P.President, CEO and CFOPPurchase+5.00K$0.57+$2.85K+14.8%38.8K after2 lots
Dec 13, 2023 (view filing)Jun 6-Dec 12190 daysLateQuinn William P.Chief Financial OfficerPPurchase+11.8K$0.9496+$11.2K+48.4%36.3K after3 lots
Dec 1, 2023 (view filing)Nov 29-302 daysEngleman EdgarDirectorSSale−148.9K$0.8687−$129.3K−37.2%251.5K after4 lots
Nov 22, 2023 (view filing)6:51 PM ETNov 211 dayVivo Capital Fund VIII, L.P. and 6 others10% OwnerSSale−3.40K$0.90−$3.06K−3.0%111.7K after3 lots
Nov 22, 2023 (view filing)Nov 211 dayEngleman EdgarDirectorSSale−1.94K$0.90−$1.75K−0.7%269.6K after2 lots
Nov 20, 2023 (view filing)9:09 PM ETNov 16-204 daysVivo Capital Fund VIII, L.P. and 6 others10% OwnerSSale−77.8K$0.9288−$72.3K−40.8%113.1K after8 lots
Nov 20, 2023 (view filing)9:09 PM ETNov 173 daysVivo Capital Fund VIII, L.P. and 6 others10% OwnerSSaleComon Stock−8.21K$0.93−$7.64K−0.4%1.98M after
Nov 20, 2023 (view filing)Nov 16-204 daysEngleman EdgarDirectorSSale−49.2K$0.9289−$45.7K−15.4%269.8K after6 lots
Jul 15, 2022 (view filing)Jul 132 daysNovo Holdings A/S10% OwnerSSale−800.0K$2.00−$1.60M−17.8%3.70M after
Feb 1, 2022 (view filing)Jun 4-Dec 6, 2021242 daysLatePerez Edith A.Chief Medical OfficerPPurchase+1.33K$12.93+$17.2KNew position1.33K after2 lots
Dec 9, 2021 (view filing)Jun 4-Dec 8188 daysLateQuinn William P.Chief Financial OfficerPPurchase+6.26K$7.05+$44.1K+45.0%20.2K after3 lots